BioCryst Pharmaceuticals, Inc. (BCRX)
BCRXNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$7.52
-0.1150 (-1.51%) today
At the close, Nov 10, 4:00 PM ET. After hours $7.53 –
- Market cap
- $1.94bn
- P/E
- 4.9
- EPS, last 4 quarters
- $1.53
- Dividend yield
- –
- Day range
- $7.45 to $7.70
- 52-week range
- $6.23 to $11.22
- Average volume
- 5.45m
- Previous close
- $7.64
Analysts
6 coveringBuy4 buy, 2 hold, 0 sell
Targets a year out average $17.00, +126.1% from here
Earnings
next estimate $0.1200Next report
Dec 2025
+1500.0%
Mar 2026
-150.0%
Jun 2026
+114.3%
Sep 2026
+40.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $406.56m | $156.41m | $218.25m | $180.29m |
| Gross profit | $397.03m | $151.04m | $214.41m | $178.72m |
| Operating income | $260.38m | -$701.60m | $98.47m | $53.33m |
| Net income | $245.84m | -$721.81m | $78.39m | $37.92m |
Last four quarters: revenue $961.51m, margin -37.4%, free cash flow $365.85m
News
8 latest- 4 Commercial-Stage Biotechs Poised for Sustained Revenue GrowthZacks · 7 hours ago
- BioCryst (BCRX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- BioCryst Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
- BioCryst Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue EstimatesZacks · 6 days ago
- Bioventus (BVS) Matches Q3 Earnings EstimatesZacks · Nov 2, 2026
- Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Zacks · Oct 30, 2026
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 29, 2026
The company
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- biocryst.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.